Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01)

The summary for the Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01)
	CFDA Number:	93.839
	CFDA Description:	Blood Diseases and Resources Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-11-186
	Document Type:	Modification to Previous Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 28, 2011
	Creation Date:	Jun 10, 2011
	Original Closing Date for Applications:	Oct 05, 2013
	Current Closing Date for Applications:	Jan 07, 2014
	Archive Date:	Feb 07, 2014
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are not allowed.
Grant Description: This FOA issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, encourages Research Project Grant (R01) applications from institutions and organizations that propose collaborative, multidisciplinary, multi-Project Director/Principal Investigator research for the development of new technologies needed to utilize stem cells in future cell therapies to treat sickle cell disease and other blood disorders. This initiative focuses on two key areas that are impediments to further progress: (1) development of techniques to efficiently generate hematopoietic cells by either differentiation of human pluripotent stem cells (PSC) or by cellular reprogramming to yield sufficient numbers of GMP quality cells for clinical evaluation; and (2) development of protocols that enable the efficient engraftment of hematopoietic cells derived from pluripotent stem cells or derived by cellular reprogramming. Each multidisciplinary application will designate two or more Project Directors/Principal Investigators. This program will be implemented in collaboration with the ongoing NHLBI Progenitor Cell Biology Consortium (http://www.progenitorcells.org/) and will add separate additional research projects. Extensive collaboration is expected between the existing Consortium Hubs, and the new group(s) are also expected to collaborate extensively with the Consortium Hubs.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-11-186.html
Grant Announcement Contact: NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Safe and Effective Instruments and Devices for Use in the Neonatal Intensive Care Units (STTR) [R41]; • Safe and Effective Instruments and Devices for Use in the Neonatal Intensive Care Units (SBIR) [R43]...; • Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34); • Clinical Trials Development Resource for Hematologic Disorders (U24); • Early-Phase Clinical Trials for Blood Cell Therapies (R01); • IMPROVED THERAPY FOR HEMOPHILIA AND HEREDITARY BLEEDING DISORDERS; • Clinical Hematology Research Career Development Program (K12); • MOLECULAR MECHANISMS UNDERLYING DIAMOND-BLACKFAN ANEMIA AND OTHER CONGENITAL BONE MARROW FAILURE SYN...; • SPECIALIZED CENTERS OF CLINICALLY ORIENTED RESEARCH (SCCOR) IN TRANSFUSION BIOLOGY AND MEDICINE; • MYELODYSPLASTIC SYNDROME (MDS): SEEKING CURE THROUGH DISCOVERY ON PATHOGENESIS AND DISEASE PROGRESSI...